ReviewCurrent opinion in molecular therapeutics2010
Gene therapy from the perspective of systems biology.
Review in Current opinion in molecular therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Complementary Gene Therapy after Revascularization with the Saphenous Vein in Diabetic Foot Syndrome.Genes · 2023Trial
- Trafficking dynamics of VEGFR1, VEGFR2, and NRP1 in human endothelial cells.PLoS computational biology · 2024Article
- Advances and challenges in gene therapy strategies for pediatric cancer: a comprehensive update.Frontiers in molecular biosciences · 2024Review
- ROS-responsive nanoparticle-mediated delivery of CYP2J2 gene for therapeutic angiogenesis in severe hindlimb ischemia.Materials today. Bio · 2022Article
- Disease pharmacokinetic-pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA-based therapies.British journal of pharmacology · 2020Article
- Discovery of High-Affinity PDGF-VEGFR Interactions: Redefining RTK Dynamics.Scientific reports · 2017Article
- Systems biology of the microvasculature.Integrative biology : quantitative biosciences from nano to macro · 2015Review
- A systems biology view of blood vessel growth and remodelling.Journal of cellular and molecular medicine · 2014Review
- Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts.Cancer medicine · 2014Article
- Article
- Heart failure gene therapy: the path to clinical practice.Circulation research · 2013Review
- Therapeutic angiogenesis for critical limb ischaemia.Nature reviews. Cardiology · 2013Review
- Endothelial cell-by-cell profiling reveals the temporal dynamics of VEGFR1 and VEGFR2 membrane localization after murine hindlimb ischemia.American journal of physiology. Heart and circulatory physiology · 2013Article
- Article
- Fundamental study of detection of muscle hypertrophy-oriented gene doping by myostatin knock down using RNA interference.Journal of sports science & medicine · 2012Article
- Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs.Molecular pharmaceutics · 2011Article
- Theoretical models for coronary vascular biomechanics: progress & challenges.Progress in biophysics and molecular biology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Gene therapy research has expanded from its original concept of replacing absent or defective DNA with functional DNA to include the manipulation (increase or decrease) of gene expression by the delivery of modified genes, siRNA or other genetic material via multiple vectors, including naked plasmid DNA, viruses and even cells. Specific tissues or cell types are targeted in order to decrease the risks of systemic or side effects. As with the development of any drug, there is an amount of empiricism in the choice of gene target, route of administration, dosing and, in particular, the scaling-up from preclinical models to clinical trials. High-throughput experimental and computational systems biology studies that account for the complexities of host-disease-therapy interactions hold significant promise in assisting in the development and optimization of gene therapies, including personalized therapies and the identification of biomarkers to evaluate the success of such strategies. This review describes some of the obstacles and successes in gene therapy, using the specific example of growth factor gene delivery to promote angiogenesis and blood vessel remodeling in ischemic diseases; anti-angiogenic gene therapy in cancer is also discussed. In addition, the opportunities for systems biology and in silico modeling to improve on current outcomes are highlighted.
Indexed as
Identifiers
20886389PMC3021921What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.